Efficacy and safety of rituximab in children and adolescents with mature B-cell non-Hodgkin's lymphoma: a Meta analysis / 中国当代儿科杂志
Chinese Journal of Contemporary Pediatrics
;
(12): 51-59, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-971039
ABSTRACT
OBJECTIVES@#To study the efficacy and safety of rituximab combined with chemotherapy in the treatment of children and adolescents with mature B-cell non-Hodgkin's lymphoma (B-NHL) through a Meta analysis.@*METHODS@#The databases including PubMed, Embase, the Cochrane Library, ClinicalTrials.gov, Web of Science, China National Knowledge Infrastructure, Wanfang Data, and Weipu were searched to obtain 10 articles on rituximab in the treatment of mature B-NHL in children and adolescents published up to June 2022, with 886 children in total. With 3-year event-free survival (EFS) rate, 3-year overall survival (OS) rate, complete remission rate, mortality rate, and incidence rate of adverse reactions as outcome measures, RevMan 5.4 software was used for Meta analysis, subgroup analysis, sensitivity analysis, and publication bias analysis.@*RESULTS@#The rituximab+chemotherapy group showed significant increases in the 3-year EFS rate (HR=0.38, 95%CI 0.25-0.59, P<0.001), 3-year OS rate (HR=0.29, 95%CI 0.14-0.61, P=0.001), and complete remission rate (OR=3.72, 95%CI 1.89-7.33, P<0.001) as well as a significant reduction in the mortality rate (OR=0.31, 95%CI 0.17-0.57, P<0.001), as compared with the chemotherapy group without rituximab. There was no significant difference in the incidence rate of adverse reactions between the two groups (OR=1.28, 95%CI 0.85-1.92, P=0.24).@*CONCLUSIONS@#The addition of rituximab to the treatment regimen for children and adolescents with mature B-cell non-Hodgkin's lymphoma can bring significant survival benefits without increasing the incidence of adverse reactions.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Inducción de Remisión
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
China
/
Linfoma de Células B
/
Rituximab
/
Supervivencia sin Progresión
Tipo de estudio:
Revisiones Sistemáticas Evaluadas
Límite:
Adolescente
/
Niño
/
Humanos
País/Región como asunto:
Asia
Idioma:
Chino
Revista:
Chinese Journal of Contemporary Pediatrics
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS